QTERN is contraindicated in patients with a history of any serious hypersensitivity reaction to the active substances or to any of the excipients, including anaphylaxis or angioedema following exposure to any dipeptidyl peptidase-4 (DPP4) inhibitor. QTERN is contraindicated in patients with a history of any serious hypersensitivity to dapagliflozin or to any of the excipients (see Precautions).